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Tiagabine (TGB) and vigabatrin (VGB) are two novel anticonvulsant compounds reported to exert their 
pharmacological effects via an action on the y-aminobutyric acid (GABA) system. We have investigated the effects 
of acute exposure of these drugs on the uptake of GABA into rat cortical astrocytes in primary culture. Astrocytes 
were prepared from the cerebral cortices of one-day-old rat pups by a mechanical dissociation technique and were 
assayed for GABA uptake activity after 21 days in culture. Tiagabine (100-300 nM) and VGB (100~~) reduced 
GABA uptake when compared to control at four hours post-exposure. GABA uptake was also reduced following 
eight and 24 hour exposures to 20011~ TGB. A combination of TGB (20011~) and VGB (100~~) treatments 
reduced GABA uptake when compared to both control and VGB treated cultures. These results support the 
efficacy of TGB as a GABA uptake inhibitor and suggest that VGB may also exert an effect by this mechanism. 
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INTRODUCTION 
Epilepsy is one of the most common neurological 
disorders affecting an estimated 50 million 
people world-wide’. The majority of the epileptic 
population can be adequately controlled with 
existing antiepileptic drugs (AEDs), although 
20% of patients remain resistant to currently 
available treatment*. Recent additions to the 
clinician’s armamentarium have, however, im- 
proved the pharmacological treatment of epi- 
lepsy, particularly in terms of side-effect profiles3. 
Two such novel compounds are vigabatrin 
(VGB) and tiagabine (TGB). Both drugs have 
been reported to exert their anticonvulsant 
actions via specific effects on the y-aminobutyric 
acid (GABA) system, VGB by an irreversible 
inhibition of the enzyme GABA-transaminase 
(GABA-T) and TGB by blockade of neuronal 
and glial GABA uptake4*‘. 
While experimental evidence supports a single 
mechanism of action for TGB6, a variety of 
reports would suggest otherwise for VGB. The 
diverse range of experimental anticonvulsant 
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profiles exhibited by a variety of neuroactive 
compounds, all of which are proposed to act as 
inhibitors of brain GABA-T’, might suggest the 
contribution of secondary mechanisms of action. 
Similarly, Bemasconi and colleagues’ demon- 
strated that the anticonvulsant effects of VGB in 
animal seizure models are not related to the time 
of maximal GABA-T inhibition. Perhaps the 
most pertinent observation, however, is one of 
rebound seizures immediately upon clinical with- 
drawal of the drug’. Such an effect would be 
inconsistent with a compound which irreversibly 
inhibits an enzyme in the brain. As a result of 
these experimental and clinical observations with 
VGB, we have investigated its action on GABA 
uptake into rat cortical astrocytes in primary 
culture and compared these effects to those 
obtained with TGB. 
MATERIALS 
One-day-old rat pups were obtained from a 
breeding colony of Sprague Dawley rats housed 
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at the Joint Animal Facility, University of 
Glasgow. Dulbecco’s modified Eagle medium 
(DMEM), house serum (HS), L-glutamine, peni- 
cillin and streptomycin were all obtained from 
Gibco BRL (Paisley, U.K.). All other chemicals 
(reagent grade) were obtained from the Sigma 
Chemical Company (Poole, U.K.). Radiolabelled 
GABA (y-[‘4C(U)]-aminobutyric acid) was ob- 
tained from NEN Research Products (Stevenage, 
U.K.). VGB (D,L-4-aminohex-5-enoic acid) and 
TGB ((R-)-(-)-l-[4,4-Bis(3-methyl-2-thienyl)-3- 
butenyll-3-piperidine-carboxylic acid, hydroch- 
loride) were obtained from Marion Merrell Dow 
(Winnersh, U.K.) and Novo Nordisk A/S (Bag- 
svaerd, Denmark), respectively. 
METHODS 
Primary culture of cerebral cortical astrocytes 
This method was devised from modifications of 
the methods of Larsson and co-workers” and 
Bender and Hertz”‘. The cerebral cortices of 
one-day-old rat pups were removed under aseptic 
conditions and cleared of attached olfactory 
bulbs, basal ganglia, hippocampal formations and 
meningeal membranes. The dissected neopallia 
were then cut into small cubes (0.5 mm’) by two 
passes (at 90’) in a McIlwain tissue chopper 
(Mickle Laboratory Engineering Company Ltd, 
Gomshall, U.K.). The chopped tissue was trans- 
ferred to a sterile glass filter (80 pm nylon mesh; 
Lockertex Ltd., Warrington, U.K.) and the 
filtrate collected in a sterile beaker. The chopped 
material was washed through the filter with 
culture medium (DMEM supplemented with 
20% (v/v) HS, 2.5 mM L-glutamine, 100 I.U./ml 
penicillin, and 100 pg/rnl streptomycin) to give a 
final volume of 3 ml/brain. The filtrate was then 
passed through a sterile needle (BD Microlance 
21G 0.8 X 40) three times. The volume of the 
resulting suspension was adjusted with culture 
medium to allow a 3 ml aliquot per culture dish in 
a ratio of 1 brain to 3 dishes. A 3 ml volume of the 
final cell suspension was plated onto 60 X 15 mm 
Falcon Primaria culture dishes (A + J Beveridge, 
Edinburgh, U.K.). The cultures were maintained 
at 37°C in an environment of 95% sir/5% CO2 
with a humidity of 290%. The culture medium 
(3 ml) was replaced every 3-4 days throughout. 
The HS concentration was reduced to 10% at the 
first medium change with a final reduction to 5% 
at the second change. After 14 days in culture the 
medium was supplemented with 0.25 mM 3’5’- 
dibutyryl cyclic adenosine monophosphate 
(CAMP) to induce cell differentiation. Penicillin 
and streptomycin were omitted from the medium 
at this stage following reports that penicillin may 
interfere with GABAergic function’*. The cul- 
tures were employed for the study of GABA 
uptake seven days after supplementation with 
CAMP. 
[14C]-GABA uptake into cultured astrocytes 
This method was devised from modifications of 
the methods of Larsson and co-workers” and Yu 
and colleagues’3. A standard balanced salt solu- 
tion (BSS) was used throughout the investigations 
of [14C]-GABA uptake. Its composition was as 
follows: 136 mM NaCl, 5 mM KCI, 0.8 mu MgS04, 
2.6 mM NaHC03, 0.4 mM KH2P04, 0.34 mM 
Na2HP04, 1.3 mM CaCl,, 5.6 mM D-glucose and 
15 mM HEPES. The solution was adjusted to 
pH 7.4 with 1 M NaOH and stored, at 4”C, for up 
to one week. BSS was warmed to 37°C prior to 
use. Cultures for investigation were removed 
from the incubator and the existing medium 
aspirated. Cultures were washed twice (2 X 2 ml) 
with BSS before being returned to the incubator 
in a further volume of BSS (3 ml) for an 
equilibration period of 20minutes. The pre- 
washed cultures were then removed from the 
incubator and the existing BSS aspirated. This 
solution was replaced by BSS (2 ml) containing 
the drug concentrations appropriate to the 
individual experiment. Control plates received 
BSS alone. All culture plates were returned to the 
incubator for a further incubation period (l- 
24 hours). After the incubation period, a further 
1 ml of BSS (with appropriate control/drug 
treatment) containing 150 PM [14C]-GABA (spe- 
cific activity = 1 mCi/mmol) was added to each 
plate. Incubation (37°C) was allowed to continue 
for five minutes before the cultures were washed 
with five volumes (2 ml) of BSS. Cells were 
removed from the plates by scraping in 1 M NaOH 
(1 ml). Aliquots were taken for protein deter- 
mination by the BIORAD method and liquid 
scintillation counting in 6 ml of Picofluor 40 
scintillation fluid (Canberra Packard, Pang- 
boume, U.K.). A Canberra Packard 2OOOCA 
TRI-CARB liquid scintillation counter (Pang- 
boume, U.K.) was employed to analyse GABA 
uptake in individual cultures in comparison to the 
dpm of standard solutions containing known 
amounts of radioligand. Results were quantified 
by the relation of GABA uptake to the protein 
concentration and expressed as pmol/minute/mg 
protein in individual cultures. 
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Determination of protein concentration 
Protein concentrations were determined by the, 
sensitive BIORAD method which relies on the 
colour change of a dye (Coomassie Brilliant Blue 
G-250). Standards were prepared over the range 
5-20 pg/ml bovine serum albumin and samples 
of unknown protein concentration were also 
diluted into this range. BIORAD dye reagent was 
diluted 1:l with water and added to standards 
and samples alike. Tubes were mixed and 
incubated at room temperature for 5 minutes and 
then read at 595 nm in a spectrophotometer 
(MR5000, Dynatech Ltd., Guernsey). Results 
were corrected for dilution and expressed in 
mg/ml. 
EXPERIMENTAL PROTOCOL 
The following studies were designed to investig- 
ate the dose- and time-dependent effects of both 
TGB and VGB on GABA uptake into primary 
cultures of rat cortical astrocytes. Individual 
studies employed control (untreated) groups and 
between 12 and 20 plates per group. 
l Study 1: The effects of TGB dose (50-500 nM) 
on GABA uptake at four hours post-treatment. 
l Study 2: The effects of VGB dose (l-500 PM) 
on GABA uptake at four hours post-treatment. 
l Study 3: The effects of 200 nM TGB on GABA 
uptake at l-24 hours post-treatment. 
l Study 4: The effects of 100 PM VGB on GABA 
uptake at 1-24 hours post-treatment. 
l Study 5: The effects of 200 nM TGB and 100 PM 
VGB, alone and in combination, on GABA 
uptake at four hours post-treatment. 
STATISTICAL METHODS 
Statistical analysis was performed using 
MINITAB for Windows statistical package (Ver- 
sion 10.1) on a Viglen 4DX266 microcomputer. 
Results were expressed as the mean percentage of 
mean control values for each group f the 
standard error of the mean (SEM). In those 
experiments evaluating dose and time related 
drug actions (Study nos. l-4), results were 
compared to control values by one-way analysis 
of variance with Dunnett correction for multiple 
comparisons. In the combination experiment 
(Study no. 5), results were compared by two 
sample r-test. 
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RESULTS 
Study 1 
TGB (100-300 IUII) significantly reduced GABA 
uptake into primary cultures of rat cortical 
astrocytes following a four hour exposure (Fig. 1). 
All other doses of TGB were without effect. 
Study 2 
VGB (100 and 250 PM) significantly reduced 
GABA uptake into primary cultures of rat 
cortical astrocytes following a four hour exposure 
(Fig. 2). All other doses of VGB were without 
effect. 
Study 3 
TGB (200 nM) significantly reduced GABA up- 
take into primary cultures of rat cortical astro- 
cytes at 4, 8 and 24 hours post-exposure (Fig. 3). 
TGB was without effect at all other time points 
investigated. 
Study 4 
VGB (100~~) was without effect on GABA 
uptake into primary cultures of rat cortical 
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Fig. 1: Effects of tiagabine (TGB) concentration on the 
uptake of [“‘Cl-GABA into rat cortical astrocytes in primary 
culture following a four hour exposure. Results (12 < n > 20) 
are expressed as the mean percentage of the control values 
and error bars denote the standard error of the mean(sem). 
Statistical significance (‘P < 0.05) was determined by 
one-way analysis of variance with Dunnett correction. 
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Fig. 2: Effects of vigabatrin (VGB) concentration on the 
uptake of [“‘Cl-GABA into rat cortical astrocytes in primary 
culture following a four hour exposure. Results (12 < n > 20) 
are expressed as the mean percentage of the control values 
and error bars denote the standard error of the mean (sem). 
Statistical significance (‘P < 0.05) was determined by 
one-way analysis of variance with Dunnett correction. 
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Fig. 3: Effects of exposure time (hours) to tiagabine (TGB; 
200 nM) on the uptake of [‘%I-GABA into rat cortical 
astrocytes in primary culture. Results (12 < n > 20) are 
expressed as the mean percentage of the control values and 
error bars denote the standard error of the mean (sem). 
Statistical significance (*PC 0.05) was determined by 
one-way analysis of variance with Dunnett correction. 
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Fig. 4: Effects of exposure time (hours) to vigabatrin (VGB; 
100 PM) on the uptake of [‘%I-GABA into rat cortical 
astrocytes in primary culture. Results (7 2 < n > 20) are 
expressed as the mean percentage of the control values and 
error bars denote the standard error of the mean (sem). 
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Fig. 5: Effects of tiagabine (TGB; 200 nM) and vigabatrin 
(VGB; 100 PM), alone and in combination, on the uptake of 
[ %I-GABA into rat cortical astrocytes in primary culture 
following a four hour exposure. Results (12 < n > 20) are 
expressed as the mean percentage of the control values and 
error bars denote the standard error of the mean (sem). 
Statistical significance (‘P < 0.001) was determined by 
two-sample t-test. 
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astrocytes at all of the time points investigated 
(Fig. 4). 
Study 5 
TGB (200n~), VGB (100~~) and combination 
treatments all significantly reduced GABA into 
primary cultures of rat cortical astrocytes when 
compared to control (Fig. 5). 
DISCUSSION 
The aims of these studies were to investigate the 
effects of TGB and VGB, alone and in combina- 
tion, on the uptake of [14C]-GABA into rat 
cortical astrocytes in primary culture. 
These drugs have previously been proposed to 
exert their pharmacological actions via single and 
specific effects on the GABAergic system4*5. 
TGB belongs to a new class of AEDs, derived 
from nipecotic acid and believed to exert their 
anticonvulsant action by blockade of GABA 
uptake into neurones and glial cell@. Recent 
evidence has suggested that GABA uptake is 
mediated by four distinct transporter proteinsI 
and that TGB is predominantly active at the 
transporter termed ‘GAT-1’ and weakly active at 
‘GAT-3’. TGB is effective against audiogenic 
seizures in DBA/2 mice5, the motor manifesta- 
tions of amygdaloid kindled seizurer? and the 
tonic and clonic components of pentylene- 
tetrazol-induced seizures in both rats and mice5. 
It has also been proposed to have efficacy against 
tonic seizures induced by maximal electroshocki6. 
TGB is currently undergoing phase III clinical 
trial for the treatment of epilepsy and initial 
reports suggest that the drug is active against both 
partial and secondary generalized seizures3. 
In these studies, TGB reduced GABA uptake 
into rat cortical astrocytes in a dose-specific 
manner. Its concentration-effect profile appeared 
to be U-shaped, however, making determination 
of an IC50 impossible. A similar dose-related 
pattern has been reported with TGB in whole 
animal seizure models5. The reason for this 
phenomenon remains unknown, and although 
higher drug doses are possibly cytotoxic, no 
parallel reduction in the protein content of 
cultures was observed in the above studies. 
Another surprising observation from these 
studies was the latency to onset of TGB action on 
GABA uptake, with the drug only being active 
after at least four hours exposure. This would not 
appear to concur with the rapid onset of TGB 
action in whole animal seizure models following 
parenteral administration5. One might speculate 
that direct application of TGB to the cell surface 
should result in immediate effect. Further studies 
employing a wider range of time intervals from 0 
to 4 hours are required in an attempt to clarify 
this apparent discrepancy. 
Vigabatrin was the first drug to enter regular 
clinical use, having been designed specifically for 
the treatment of epilepsy”. It has been proposed 
to exert its anticonvulsant effects by an irrever- 
sible inhibition of GABA-p, the enzyme respon- 
sible for the metabolic degradation of the 
inhibitory neurotransmitter GABA. Vigabatrin 
has demonstrated efficacy against a range of 
experimental seizures including those induced by 
picrotoxin’ and amygdaloid kindling” and is also 
effective in genetic models of reflex epilepsy”. 
At concentrations of 100 and 250~~, VGB 
significantly blocked astrocytic. GABA uptake. 
These concentrations are close to that reported as 
the IC50 for inhibition of GABA-T in the same 
cell type”. This previously unreported mechan- 
ism of VGB action might help to explain the 
diverse range of experimental anticonvulsant 
profiles exhibited by a variety of GABA-T 
inhibitors’. It may also underlie the lack of 
relationship between the time of maximal 
GABA-T inhibition and the anticonvulsant 
effects of VGB in animal seizure models’ and the 
observation of rebound seizures immediately 
upon clinical withdrawal of the drug’. 
If one considers the structural similarity be- 
tween VGB and GABA, it is possible to 
speculate that the blockade of GABA uptake 
afforded by VGB may be the result of a simple 
competitive reaction between the two molecules 
at one or more of the four reported GABA 
uptake carriers . I4 Although previous studies have 
suggested that VGB is not a substrate for the 
‘GABA transporter’21, the drug is believed to 
enter cells via some high affinity uptake system”. 
With recent evidence proposing the existence 
of multiple GABA uptake carriers14, it is possible 
that VGB has a specific action at one or more of 
these newly discovered targets. The GABA 
uptake carrier ‘GAT-3’ might represent the most 
likely site of VGB action in this respect. 
p-alanine, a specific substrate of GABA-T22, has 
been shown to selectively block GABA transport 
via the ‘GAT3’ carrier. It is possible that 
structural similarities facilitate the binding of 
GABA, @alanine and VGB at the active sites of 
both GABA-T and the ‘GAT-3’ transporter. 
In cultures exposed to a combination of both 
TGB and VGB, the inhibition of GABA uptake 
was greater than that observed when either drug 
was administered alone. This effect did, however, 
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appear to be i&a-additive and would thus 
suggest a similar site of action for both drugs. If 
TGB and VGB were to act at independent uptake 
sites one would expect to observe a total 
inhibition of GABA uptake equal to the sum of 
inhibitions observed with both drugs alone. This 
evidence might support a contributory role for 
VGB on the TGB-mediated blockade of GABA 
uptake at the ‘GAT-3’ transporter. 
In conclusion, these results suggest that both 
TGB and VGB block GABA uptake into primary 
cultures of rat cortical astrocytes. Further studies 
to determine the basis of the U-shaped 
dose-response to TGB and its lack of effect prior 
to four hours are required. In terms of VGB, a 
more detailed evaluation of this novel mechanism 
is planned. Further investigations of its dose- and 
time-dependency and cell specificity, together 
with evaluation of the relationship between this 
and the intracellular effects of VGB are clearly 
required. Characterization of the GABA uptake 
blockade observed with VGB may help to 
determine its relative importance as an additional 
mechanism of anticonvulsant action. 
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